Timing Strategies of Direct-Acting Antivirals and Biologics Administration in HCV-Infected Subjects with Inflammatory Bowel Diseases

• Egile Nagusiak: Nicola Imperatore (Egilea), Fabiana Castiglione (Egilea), Antonio Rispo (Egilea), Anna Sessa (Egilea), Nicola Caporaso (Egilea), Filomena Morisco (Egilea)
• Formatua: Liburua
• Argitaratua: Frontiers Media S.A., 2017-11-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Background: In the last years, inflammatory bowel disease (IBD) and hepatitis C virus (HCV) infection management has completely changed. However, the role of direct-acting antivirals (DAAs) and the correct timing of antiviral drugs administration in IBD patients needing biologics has not been evalua...